Mylan and Biocon Announce Positive CHMP Opinion for Ogivri(R), Biosimilar Trastuzumab
HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Oct. 19, 2018 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the European Medicines Agency's Committee for... Biopharmaceuticals, Generics, Oncology, Regulatory Mylan, Biocon, Ogivri, Herceptin, trastuzumab, breast cancer, biosimilar (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 19, 2018 Category: Pharmaceuticals Source Type: news

HER2+ early breast cancers where shorter-course trastuzumab could be an option
(European Society for Medical Oncology) Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, according to a subgroup analysis of the Short-HER trial reported at ESMO 2018 Congress in Munich. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 19, 2018 Category: Cancer & Oncology Source Type: news

Women suffer more chemo side effects than men
Study focused on chemo for stomach cancer Related items fromOnMedica Cancer patients using complementary meds die sooner Cancer strategies failed to improve one-year survival FOB associated with rise in all-cause mortality Antivirals cut liver cancer risk after hepatitis C NICE recommends Herceptin for gastric cancer (Source: OnMedica Latest News)
Source: OnMedica Latest News - October 19, 2018 Category: UK Health Source Type: news

Roche ’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival, iDFS) compared to Herceptin® (trastuzumab) as an adjuvant (after surgery) treatment in people with HER2-positive early breast cancer (eBC) who have residual di sease (pathological invasive residual disease in the breast and/or axillary nodes) present following neoadjuvant (before surgery) treatment. (Source: Roche Media News)
Source: Roche Media News - October 15, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival, iDFS) compared to Herceptin® (trastuzumab) as an adjuvant (after surgery) treatment in people with HER2-positive early breast cancer (eBC) who have residual di sease (pathological invasive residual disease in the breast and/or axillary nodes) present following neoadjuvant (before surgery) treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - October 15, 2018 Category: Pharmaceuticals Source Type: news

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)
Mutations in ERBB2, the gene encoding epidermal growth factor receptor (EGFR) family member HER2, are common in and drive the growth of "HER2-negative" (not ERBB2 amplified) tumors but are rare in "HER2-positive" (ERBB2 amplified) breast cancer. We analyzed DNA-sequencing data from HER2-positive patients and used cell lines and a patient-derived xenograft model to test the consequence of HER2 mutations on the efficacy of anti-HER2 agents such as trastuzumab, lapatinib, and neratinib, an irreversible pan-EGFR inhibitor. HER2 mutations were present in ~7% of HER2-positive tumors, all of which were metasta...
Source: Signal Transduction Knowledge Environment - October 9, 2018 Category: Science Authors: Cocco, E., Javier Carmona, F., Razavi, P., Won, H. H., Cai, Y., Rossi, V., Chan, C., Cownie, J., Soong, J., Toska, E., Shifman, S. G., Sarotto, I., Savas, P., Wick, M. J., Papadopoulos, K. P., Moriarty, A., Cutler, R. E., Avogadri-Connors, F., Lalani, A. Tags: STKE Research Articles Source Type: news

Can Trastuzumab Duration Be Shortened in HER2-Positive Breast Cancer?
The Short-HER study was unable to show noninferiority of 9 weeks of trastuzumab compared with the standard 1 year in women with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - October 4, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

For HER2+ Breast Cancer, Anthracyclines and Trastuzumab Are Safer in Sequence For HER2+ Breast Cancer, Anthracyclines and Trastuzumab Are Safer in Sequence
Treating operable HER2-positive breast cancer with anthracyclines and trastuzumab in sequence works as well as giving them together, and it's safer, researchers suggest.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 21, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Cardiac Monitoring Needed for High - Risk Breast Cancer Patients
Trastuzumab, certain chemo treatments increase patient risk of heart failure (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 20, 2018 Category: Cancer & Oncology Tags: Cardiology, Gynecology, Oncology, Pharmacy, Journal, Source Type: news

Cardiac Monitoring Needed for High-Risk Breast Cancer Patients
THURSDAY, Sept. 20, 2018 -- Risk of cardiotoxicity is higher for patients receiving trastuzumab and/or anthracyclines for the treatment of breast cancer, according to a study published in the Aug. 1 issue of JACC: Cardiovascular Imaging. Mariana L.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 20, 2018 Category: Pharmaceuticals Source Type: news

Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin(R)) In Canada
SAN DIEGO, Sept. 17, 2018 -- (Healthcare Sales & Marketing Network) -- Halozyme Therapeutics, Inc. (NASDAQ :HALO ) today announced that Roche has received approval from Health Canada for a subcutaneous (SC) formulation of trastuzumab (Herceptin SC) for th... Biopharmaceuticals, Oncology, Regulatory Halozyme Therapeutics, Genentech, trastuzumab, Herceptin, hyaluronidase (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 17, 2018 Category: Pharmaceuticals Source Type: news

Does Sequential vs Concurrent Treatment Change Outcomes in HER2+ Breast Cancer?
Outcomes for patients with HER2-positive breast cancer did not differ when treated with sequential chemotherapy plus trastuzumab compared with a concurrent approach. (Source: CancerNetwork)
Source: CancerNetwork - September 7, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Drug Conjugate Advances for Poor-Prognosis NSCLC
(MedPage Today) -- Good results in small study of trastuzumab linked to antimicrotubule agent (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 4, 2018 Category: Hematology Source Type: news

Drug Conjuagate Advances for Poor-Prognosis NSCLC
(MedPage Today) -- Good results in small study of trastuzumab linked to antimicrotubule agent (Source: MedPage Today Pulmonary)
Source: MedPage Today Pulmonary - September 2, 2018 Category: Respiratory Medicine Source Type: news

Cardiac Monitoring Lacking in Patients With Breast Cancer Cardiac Monitoring Lacking in Patients With Breast Cancer
Less than half of women receiving trastuzumab underwent guideline-recommended cardiac monitoring, but observers suggest that more tailored monitoring may be the way forward.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

High-risk breast cancer patients need cardiac monitoring
Some chemotherapy treatments for breast cancer increase a woman's risk of heart...Read more on AuntMinnie.comRelated Reading: ASTRO: Imaging, radiation oncology increasingly work as one Breast cancer patients aren't getting heart disease treatment CE-MRI predicts survival in breast cancer patients after chemo JNM: Cancer patients need cardiac review Trastuzumab + RT = no cardiac risk in breast cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 8, 2018 Category: Radiology Source Type: news

Heart Monitoring a Must for Breast Cancer Patients on Herceptin
(Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - August 8, 2018 Category: Cancer & Oncology Source Type: news

Adding TKIs Could Increase Responses in Metastatic HER2+ Breast Cancer
A laboratory study found that combining anti-HER2 TKIs with trastuzumab and pertuzumab can result in enhanced anticancer activity in HER2+ breast cancer cell lines. (Source: CancerNetwork)
Source: CancerNetwork - August 7, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Women On Herceptin Need Regular Heart Checks
Women who take the chemotherapy drug trastuzumab (Herceptin) for HER2-positive breast cancer can be at higher risk for heart failure and should have their hearts monitored during treatment, new research finds. The complication is not common, and in many cases, the benefits of the chemotherapy still outweigh the risks. But regular checks should be a priority. (Source: WebMD Health)
Source: WebMD Health - August 7, 2018 Category: Consumer Health News Source Type: news

Heart Monitoring a Must for Breast Cancer Patients on Herceptin
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 7, 2018 Category: Cancer & Oncology Tags: Cardiology, Gynecology, Oncology, Pharmacy, Preventive Medicine, News, Source Type: news

Heart Monitoring a Must for Breast Cancer Patients on Herceptin
TUESDAY, Aug. 7, 2018 -- The widely used chemotherapy drug trastuzumab (Herceptin) can be life-saving for women with HER2-positive breast cancer, a particularly aggressive form of the disease. But new research now adds to mounting evidence that the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 7, 2018 Category: General Medicine Source Type: news

Heart Monitoring a Must for Breast Cancer Patients on Herceptin
Title: Heart Monitoring a Must for Breast Cancer Patients on HerceptinCategory: Health NewsCreated: 8/7/2018 12:00:00 AMLast Editorial Review: 8/7/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 7, 2018 Category: Cancer & Oncology Source Type: news

Heart Monitoring a Must for Breast Cancer Patients on Herceptin
(Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - August 7, 2018 Category: Cancer & Oncology Source Type: news

Herceptin Tied to Heart Issues in Breast Ca Patients
(MedPage Today) -- Adherence to cardiac monitoring less than ideal in trastuzumab recipients (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - August 6, 2018 Category: Urology & Nephrology Source Type: news

Trastuzumab Tied to Heart Issues in Breast Ca Patients
(MedPage Today) -- Adherence to cardiac monitoring less than ideal in recipients (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 6, 2018 Category: Cardiology Source Type: news

Doctors could save £200m a year if they stop prescribing pricey drugs
NHS Improvement believes that some of the biggest savings in the UK could be made if doctors stopped prescribing the breast cancer wonder drug Herceptin. (Source: the Mail online | Health)
Source: the Mail online | Health - July 31, 2018 Category: Consumer Health News Source Type: news

How doctors could save £200million a year if they stop prescribing expensive drugs
NHS Improvement believes that some of the biggest savings in the UK could be made if doctors stopped prescribing the breast cancer wonder drug Herceptin. (Source: the Mail online | Health)
Source: the Mail online | Health - July 31, 2018 Category: Consumer Health News Source Type: news

Dr Reddy's launches Hervycta to treat cancer in India
Quoting Ipsos data, the company said the Herceptin and its biosimilars had India sales of Rs 290 crore for the most recent 12 months ending in December 2017. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 26, 2018 Category: Pharmaceuticals Source Type: news

Trastuzumab Increases PFS in Women With HER2/neu Uterine Cancer Trastuzumab Increases PFS in Women With HER2/neu Uterine Cancer
This well-done study should prompt oncologists to consider adding trastuzumab to carboplatin-paclitaxel treatment for women with advanced HER2/neu-positive uterine cancer, says Dr Maurie Markman.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Gene Mutations Dictate Treatment in NCI Clinical Trial
More than 40 patients with mesothelioma have been screened for NCI-MATCH, the novel clinical trial pairing tumor-related gene abnormalities with a drug targeting the corresponding mutation, regardless of cancer type. The multicenter program is the largest precision medicine clinical trial ever conducted, with more than 5,500 patients already participating nationwide. The National Cancer Institute (NCI) sponsors the phase II trial called Molecular Analysis for Therapy Choice (MATCH), which opened in 2015. The study was designed for patients with various solid tumors, myeloma and lymphoma that have progressed after standard-...
Source: Asbestos and Mesothelioma News - July 5, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Will a Trastuzumab Biosimilar Work in Early HER2+ Breast Cancer?
The trastuzumab biosimilar ABP 980 showed noninferiority to trastuzumab in a large trial of patients with early HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 20, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Trastuzumab Biosimilar on Par With Reference Product in Early Breast Cancer Trastuzumab Biosimilar on Par With Reference Product in Early Breast Cancer
Safety, efficacy and clinical outcomes were similar for Amgen's trastuzumab biosimilar ABP 980 and the trastuzumab reference product in women with HER2-positive early breast cancer in the LILAC study, researchers reported June 4 at the 2018 ASCO Annual Meeting.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Tucatinib Shows Promise in Phase I Study of HER2-Positive Breast Cancer
The HER2 TKI tucatinib plus capecitabine or trastuzumab were reasonably well tolerated and showed antitumor activity in a phase I trial of HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Many Breast Cancer Patients Can Safely Skip Chemo, Major Study Finds
CHICAGO (CBS News/AP) — Most women with the most common form of early-stage breast cancer can safely skip chemotherapy without hurting their chances of beating the disease, doctors are reporting from a landmark study that used genetic testing to gauge each patient’s risk. The study is the largest ever done of breast cancer treatment, and the results are expected to spare up to 70,000 patients a year in the United States and many more elsewhere the ordeal and expense of these drugs. “The impact is tremendous,” said the study leader, Dr. Joseph Sparano of Montefiore Medical Center in New York. Most wo...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 4, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Breast Cancer Chemotherapy Source Type: news

NCI-MATCH precision medicine clinical trial releases new findings
(ECOG-ACRIN Cancer Research Group) The released data is from three treatment arms, all single-arm phase 2 studies: the drug taselisib in patients with mutations in the PIK3CA gene (Arm I); the drug ado-trastuzumab emtansine (T-DM1) in patients with HER2-overexpressing tumors (Arm Q); and the drug AZD4547 in patients with mutations in the FGFR pathway (Arm W). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 4, 2018 Category: Cancer & Oncology Source Type: news

Most Women With Breast Cancer Can Skip Chemo, According to New Study
(CHICAGO) — Most women with the most common form of early-stage breast cancer can safely skip chemotherapy without hurting their chances of beating the disease, doctors are reporting from a landmark study that used genetic testing to gauge each patient’s risk. The study is the largest ever done of breast cancer treatment, and the results are expected to spare up to 70,000 patients a year in the United States and many more elsewhere the ordeal and expense of these drugs. “The impact is tremendous,” said the study leader, Dr. Joseph Sparano of Montefiore Medical Center in New York. Most women in this ...
Source: TIME: Health - June 3, 2018 Category: Consumer Health News Authors: Marilynn Marchione / AP Tags: Uncategorized healthytime onetime Women's Health Source Type: news

Most Women With Breast Cancer Can Skip Chemo, According to New Study
(CHICAGO) — Most women with the most common form of early-stage breast cancer can safely skip chemotherapy without hurting their chances of beating the disease, doctors are reporting from a landmark study that used genetic testing to gauge each patient’s risk. The study is the largest ever done of breast cancer treatment, and the results are expected to spare up to 70,000 patients a year in the United States and many more elsewhere the ordeal and expense of these drugs. “The impact is tremendous,” said the study leader, Dr. Joseph Sparano of Montefiore Medical Center in New York. Most women in this ...
Source: TIME: Science - June 3, 2018 Category: Science Authors: Marilynn Marchione / AP Tags: Uncategorized healthytime onetime Women's Health Source Type: news

European Commission approves Roche ’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
Roche today announced that the European Commission (EC) has approved Perjeta ® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - June 1, 2018 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
Roche today announced that the European Commission (EC) has approved Perjeta ® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence. (Source: Roche Investor Update)
Source: Roche Investor Update - June 1, 2018 Category: Pharmaceuticals Source Type: news

Trastuzumab for 6 Months Instead of 1 Year? Trastuzumab for 6 Months Instead of 1 Year?
The standard of care for HER2-positive breast cancer is trastuzumab (Herceptin) for a year; but could half that be enough?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Trastuzumab Emtansine in HER2 Metastatic Breast Cancer Trastuzumab Emtansine in HER2 Metastatic Breast Cancer
Recent survival results lead some to question the optimal sequence for trastuzumab emtansine in metastatic breast cancer.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 21, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Breast cancer treatment time could be HALVED
British research from the University of Warwick and the University of Cambridge has revealed the amount of time a person needs on herceptin could be halved from 12 months to six (stock). (Source: the Mail online | Health)
Source: the Mail online | Health - May 17, 2018 Category: Consumer Health News Source Type: news

Nigeria:Roche Launches Innovative Medicine Against Breast Cancer in Nigeria
[This Day] Swiss multinational, Roche has launched the subcutaneous formulation of Herceptin, its flagship breast cancer drug in Nigeria. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 17, 2018 Category: African Health Source Type: news

Shorter-Duration Trastuzumab as Effective for HER2+ Early Breast Cancer
Women with HER2-positive early breast cancer achieved similar disease-free survival with 6 months of adjuvant trastuzumab compared with a 12-month duration, according to the phase III PERSEPHONE trial. (Source: CancerNetwork)
Source: CancerNetwork - May 17, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Breast Cancer HER2-Positive Breast Cancer SiteTerms/www.cannabissciencetech.com/News Source Type: news

Breast Cancer Patients May Shorten Herceptin Regimen: Study
Title: Breast Cancer Patients May Shorten Herceptin Regimen: StudyCategory: Health NewsCreated: 5/16/2018 12:00:00 AMLast Editorial Review: 5/17/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 17, 2018 Category: Cancer & Oncology Source Type: news

Good News on Early Breast Cancer: Herceptin Treatment Can Be Shortened
A large, new study shows that the treatment regimen, typically recommended for a year, can be just as effective at 6 months, reducing serious side effects and costs. (Source: NYT Health)
Source: NYT Health - May 16, 2018 Category: Consumer Health News Authors: DENISE GRADY Tags: Breast Cancer Herceptin (Drug) Genentech Inc Earl, Helena M side effects Source Type: news

Breast Cancer Patients May Shorten Herceptin Regimen: Study
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 16, 2018 Category: Cancer & Oncology Tags: Gynecology, Oncology, News, Source Type: news

Six Months of Trastuzumab Equal to 12 in Breast Ca
(MedPage Today) -- Similar outcomes and less cardiotoxicity, but more research needed (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - May 16, 2018 Category: OBGYN Source Type: news